by
Liam Cosgrove
My articles My booksMy videos
Follow on:

Our healthcare system is broken, a fact nobody would have disputed in precovid days. Regulatory capture is a reality, and the pharmaceutical industry is fraught with examples. Yet we trusted private-public partnerships to find an optimal solution to a global pandemic, assuming a crisis would bring out the best in historically corrupt institutions.

Here is a brief list of less-than-savory behavior demonstrated by our titans of healthcare: 

• Pfizer and Johnson & Johnson plead guilty to “misbranding with the intent to defraud or mislead” and paying “kickbacks to health care providers to induce them to prescribe [their] drugs,” resulting in fines of $2.3 billion in 2009 and $2.2 billion in 2013, respectively. 
• Pfizer settled another lawsuit for “manipulating studies” and “suppressing negative findings” just a few years later. 
• Moderna has never developed an approved drug, yet one of their board members was placed in charge of Operation Warp Speed. This certainly is unrelated to the fact that they received the most federal vaccine research and development funding and have received over $6 billion from our government since the start of the pandemic.
• Gilead Sciences paid $97 million in fines, because it “illegally used a non-profit foundation as a conduit to pay the Medicare co-pays for its own drug.”
• In 2005, AstraZeneca’s drug Crestor was shown to be linked to a life-threatening muscle disease while the company withheld evidence of this and two dozen other effects from the public.
• In 2012, GlaxoSmithKline paid $3 billion in fines, as it “failed to include certain safety data” relating to their drug, since labeled as connected to heart failure and attacks.

Thankfully, our public health guardians are in place to protect us from the greed and deceit of the private sector, right? Wrong. Enjoy another brief list:

• The Food and Drug Administration (FDA) worked behind the scenes with company Biogen to alter previously conducted trials of their $56,000 per year Alzheimer’s treatment, and “by removing the subset of people for whom the drug didn’t work, they found a slight statistical effect in favor of the drug.” Even after doing this, an advisory committee voted 10–0 against approving the drug. The FDA approved the drug anyway, causing three committee members to resign.
• In that case, the third-party advisors did the right thing. This is not always the case: a study by Science Magazine tracking 107 FDA advisors for four years found that 62 percent received money from related drug makers, with 25 percent receiving over $100,000 and 6 percent receiving over $1 million. It only takes a few corrupt advisors to fix a panel and feign medical consensus.
• In 2017, it was revealed that the acting Centers for Disease Control and Prevention (CDC) director for heart disease and stroke prevention had been secretly communicating with Coca-Cola, providing guidance on how “to influence world health authorities on sugar and beverage policy matters.”

The American healthcare system remains mired in good old-fashioned crony capitalism, fascism, corporatism, mercantilism, protectionism … fancy words for when private companies work with governments to subvert the forces of competition. The suppression of research into off-patent drugs is a nasty symptom of this problem.

While there are countless drugs to which this applies, we will discuss ivermectin. First, addressing the drug’s dismissal by its own manufacturer, Merck, let it be known that ivermectin is no longer under patent. Merck no longer owns exclusive rights to the drug’s production. The forces of competition have been bestowed upon the drug, thus making it far cheaper. Meanwhile, Merck is also currently rolling out an oral covid treatment, which the US government is providing $1.2 billion in funding to research. This would be under patent and may explain the company’s opposition to using ivermectin.

The usefulness of ivermectin remains debatable. However, it’s important to note that in early April 2020,  a study at the University of Monash in Australia suggested it can be effective. Moreover, the drug is FDA approved, has existed for forty years, won a Nobel Prize, and is extremely safe when used at recommended levels. Given the crisis and ivermectin’s safety—safe even if not conferring big benefits for covid sufferers—the rush to condemn use of the drug appears suspect. Indeed, a week after the Australian study was published, the FDA advised against using ivermectin for COVID-19 treatment, forcing desperate people to the black market and to self-prescribe versions of the drug intended for animals.

The FDA noted subsequently that “additional testing is needed.” Yet, to date, there has not been a single completed government-funded study on the effectiveness of ivermectin against covid-19. Meanwhile, they have funneled billions toward research into vaccines and patented treatments. The National Institutes of Health (NIH) funded trials for remdesivir, still under patent with Gilead, despite it being less effective and having more severe side effects than ivermectin. The FDA approved remdesivir under emergency use authorization (EUA) despite published trials, later stating “remdesivir was not associated with statistically significant clinical benefits.”

One would think that if “additional testing” is so important, the US government might be interested in funding research to examine the potential benefits of cheap, safe, and proven drugs that have shown some promise in treating covid. But that’s clearly not what going on. Funding is geared toward helping huge pharmaceutical companies develop new patented drugs. As long Big Pharma wants it, and if there's a profit to be made, apparently our government will be there to provide funding.

You Might Also Like

SNB Sight Deposits: Inflation is there, CHF must Rise

2021-09-13

Sight Deposits have risen by +0.2 bn CHF, this means that the SNB is intervening and buying Euros and Dollars.

The Demise of the Gold Standard

2021-08-17

This is the fiftieth anniversary of the demise of the gold standard and the beginning of the current fiat paper standard. Many will say “good riddance” to gold and “thank goodness” for the “good ole greenback”! Reflection, however, produces an alternative conclusion.

An Anatomy of Failure: China’s Wind Power Development

2021-08-13

Abstract: China is currently the world’s largest installer of wind power. However, with twice the installed wind capacity compared to the United States in 2015, the Chinese produce less power. The question is: Why is this the case? This article shows that Chinese grid connectivity is low, Chinese firms have few international patents, and that export is low even though production capacity far exceeds domestic production needs.

Government Land Ownership and Management

2021-08-03

Recorded at the Mises Institute in Auburn, Alabama, on July 21, 2021.

Fiat Money Economies Are Built on Lies

2021-07-21

Now and then, it pays to take a step back to get a broader perspective on things, to look beyond the daily financial news, to see through the short-term ups and downs in the market to find out what is really at the heart of the matter. If we do that, we will not miss the fact that we are living in the age of fiat currencies, a world in which basically everything bears their fingerprints: the economic and financial system, politics—even people’s cultural norms, values, and morals will not escape the broader consequences of fiat currencies.

Money Supply Growth Dropped in May to a 15-Month Low

2021-07-08

Money supply growth slowed again in May, falling for the third month in a row, and to a 15-month low. That is,  money supply growth in the US has come down from its unprecedented levels, and if the current trend continues will be returning to more "normal" levels.

The Fed Plans to Raise Interest Rates—Years from Now

2021-06-21

On Wednesday, the Federal Reserve’s Federal Open Market Committee voted to continue with a target federal funds rate of 0.25 percent, and to continue with large-scale asset purchases. According to the committee’s press release:

A Dozen Dangerous Presumptions of Crisis Policymaking

2021-04-24

Congress and the president have adopted many critically important policies in great haste during brief periods of perceived national emergency. During the first “hundred days” of the Franklin D. Roosevelt administration in the spring of 1933, for example, the government abandoned the gold standard, enacted a system of wide-ranging controls, taxes, and subsidies in agriculture, and set in motion a plan to cartelize the nation’s manufacturing industries.